Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 3Phase 1 2Phase 4 1Phase 3 1

Status

Completed 5Terminated 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 282Carcinoma, Non-Small-Cell Lung 253Leukemia, Myeloid, Acute 190Breast Neoplasms 153Melanoma 151Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 114Lymphoma 113Leukemia, Lymphocytic, Chronic, B-Cell 108Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 86Prostatic Neoplasms 83Lung Neoplasms 82Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 68Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 51

Interventions

sotrovimab 1Specimen Handling 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × COVID-19 × Clear all
NCT05135650 2025-02-13

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

Fred Hutchinson Cancer Center

Phase 1 Terminated
20 enrolled 17 charts
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

NCT04803227 2022-01-04

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

Histogen

Phase 1 Terminated
13 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡